GlassScriptPhysician profile
Mary C Moree
NPI 1235457714
$6,205.65
in general payments reported to CMS, 2019-2025
40 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $1,125 · 2021: $1,507 · 2022: $739 · 2023: $965 · 2024: $1,046 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,166.64 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $675.92 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $652.77 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $547.63 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $510.26 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $338.24 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $320.41 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $245.42 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $174.62 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.10 | 2020-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $151.36 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $147.13 | 2019-2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Mylan Specialty L.P. | $143.43 | 2019-2024 | Yupelri |
| Exact Sciences Corporation | $135.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $99.38 | 2020-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Moree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.